RCS - Oxford Biomedica PLC - OXB to participate in investor conferences

Oxford BioMedicaAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251027:nRSa8188Ea&default-theme=true

RNS Number : 8188E  Oxford Biomedica PLC  27 October 2025

 

 

 

OXB to participate in upcoming investor conferences and events

 

Oxford, UK - 27 October 2025: OXB (LSE: OXB), a global quality and
innovation-led cell and gene therapy CDMO, today announces that members of its
senior management team, including Dr. Frank Mathias, Chief Executive Officer,
and Dr. Lucy Crabtree, Chief Financial Officer, will participate in the
following upcoming investor conferences and events. Details are provided
below.

 

 

Conferences

 

Stifel Healthcare Conference (New York)

·      Date: 11 November 2025

·      Fireside chat: 13:20 ET / 18:20 GMT

 

Jefferies Global Healthcare Conference (London)

·      Date: 18 November 2025

·      Presentation: 11:30 GMT / 06:30 ET

 

Events

 

Jefferies C-Suite "Back to School" Fireside Chat (Virtual)

·      Date: 4 November 2025

 

 

Live webcasts and recordings of presentations, where available, will be
accessible under 'Results, Reports, Presentations & Webcasts' in the
Investor Relations section of OXB's website at www.oxb.com
(http://www.oxb.com) .

 

For details of other upcoming financial events, please refer to the Company's
investor calendar at https://oxb.com/investor-events/
(https://oxb.com/investor-events/) .

 

-Ends-

 

Enquiries:

 

OXB:

T: +44 (0) 1865 509 737 / E: ir@oxb.com (mailto:ir@oxb.com)

Sophia Bolhassan, Head of Investor Relations

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities range
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

OXB offers a vast number of technologies for viral vector manufacturing,
including a 4th generation lentiviral vector system (the TetraVecta™
system), a dual-plasmid system for AAV production, suspension and perfusion
process using process enhancers and stable producer and packaging cell lines.

 

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It
has development and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com
(http://www.oxb.com) and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPKQBPPBDDNKB



            Copyright 2019 Regulatory News Service, all rights reserved